5472-38-8

Usage

Uses

Used in Organic Synthesis:
DIETHYL FORMYLSUCCINATE is used as a reagent for the preparation of various organic compounds, facilitating the introduction of the formyl group into organic molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, DIETHYL FORMYLSUCCINATE is used as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications.
Used in Agrochemical Production:
DIETHYL FORMYLSUCCINATE plays a role in the synthesis of agrochemicals, serving as an intermediate in the production of compounds used in agriculture to protect crops and enhance yields.
Used in Fine Chemicals Synthesis:
DIETHYL FORMYLSUCCINATE is utilized as an intermediate in the synthesis of fine chemicals, which are high-purity chemicals used in various specialized applications.
Used in Fragrance and Flavor Production:
DIETHYL FORMYLSUCCINATE is used in the production of fragrances and flavoring agents, adding to the sensory characteristics of various consumer products.
Used in Polymer and Plastics Manufacturing:
It is also employed in the manufacturing of polymers and plastics, contributing to the development of materials with specific properties for diverse applications.

InChI:InChI=1/C9H14O5/c1-3-13-8(11)5-7(6-10)9(12)14-4-2/h6-7H,3-5H2,1-2H3

Upstream product

• 585-68-2 aconic acid 
• 64-17-5 ethanol 
• 109-94-4 formic acid ethyl ester 
• 123-25-1 succinic acid diethyl ester 
• 623-91-6 diethyl Fumarate 
• 71-43-2 benzene 
• 60-29-7 diethyl ether 
• 141-05-9 Diethyl maleate 

Downstream Products

• 51251-11-7 diethyl ethylsuccinate 
• 70145-31-2 diethyl α-(ethoxymethylene)succinate 
• 123-25-1 succinic acid diethyl ester 
• 61383-45-7 anilinomethylene-succinic acid diethyl ester 
• 20763-91-1 uracil-5-ylacetic acid 
• 102596-23-6 (3,4,3',4'-tetramethoxy-benzhydryl)-succinic acid 
• 70145-29-8 diethyl 2-(diethoxymethyl)succinate 
• 14273-42-8 (2-methyl-6-oxo-1,6-dihydro-pyrimidin-5-yl)-acetic acid ethyl ester 
• 102076-52-8 [(N-methyl-anilino)-methylene]-succinic acid diethyl ester 
• 10138-10-0 ethyl 4-oxobutanoate 
• 54600-85-0 2,5-dimethyl-3,6-diphenylpyrazine 
• 5204-92-2 ethyl 5-oxotetrahydro-3-furancarboxylate 
• 885702-37-4 [4-hydroxy-2-(3,4,5-trimethoxy-phenylamino)-pyrimidin-5-yl]-acetic acid ethyl ester 
• 885702-39-6 [4-chloro-2-(3,4,5-trimethoxy-phenylamino)-pyrimidin-5-yl]-acetic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis method of thiazolidinopyrimidinone acetic acid

The synthesis method comprises the following specific steps: (1) the compound II is a raw material, tetrahydrofuran is taken as a solvent, and the compound III is generated by reacting with ethyl formate under the action of sodium hydride. (2) Compound III and Compound V react in absolute ethanol to form compound IV. (3) Compound IV reacted with methanesulfonic acid in glacial acetic acid to form thiazolidinopyrimidinone acetic acid, i.e. compound i. The present invention is simple to operate, high in yield and suitable for industrial production.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Insecticide dinotefuran intermediate 3 - hydroxy methyl tetrahydrofuran synthetic method

The invention discloses a synthetic method of pesticide dinotefuran intermediate 3-hydroxymethyl tetrahydrofuran, and the synthetic method is as follows: reacting compound succinic acid dialkyl ester with formic acid alkyl ester in the presence of a strong alkali to obtain a compound III, then obtaining a compound II by a reduction reaction, finally, in the presence of an acid catalyst, obtaining a compound shown as formula I by a dehydration cyclization reaction, and R or R ' respectively independently represents C1-5 alkyl. The synthetic method is low in raw material cost, simple in reaction operation, less in pollution, high in yield of each step, 99% in the yield of the reducing step, and suitable for industrial production.

Synthesis and in?vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes

The increasing incidence of Alzheimer's disease (AD) worldwide is a major public health problem. Current treatments provide only palliative solutions with significant side effects. Therefore, new efficient treatment options and novel early diagnosis tools are urgently needed. Recently, strong pre-clinical evidences suggested that phosphodiesterase 5 (PDE5) may be clinically relevant both as biomarker and drug-target in AD. In this study, we intended to develop a new radiofluorinated tracer for the visualisation of PDE5 in brain using PET imaging. Based on currently known PDE5 inhibitors, a series of novel fluorinated compounds bearing a quinoline core have been synthesised via multi-steps reaction pathways. Their affinity for PDE5 and selectivity over other PDE families have been investigated. According to the data collected from this in vitro screening, fluorinated derivatives 24a, b bearing a fluoroethoxy group at the C-3 position of the quinoline core appeared to be the most promising structures and will be further radiolabelled with fluorine-18 for in vitro and in vivo evaluations as PET radiotracer for neuroimaging of PDE5.

Asymmetric Reduction of Lactam-Based β-Aminoacrylates. Synthesis of Heterocyclic β2-Amino Acids

The ability to affect asymmetric reduction of heterocyclic β-aminoacrylates 1 (n = 1-3) has been assessed with pyrrolidine and piperidone variants generating the corresponding N-heterocyclic β2-amino acids 3b and 5b with high enantioselectivity

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.